| Description | This product is a human neutralizing antibody clone CC6.33, which targets the Class 3 epitope site that is distinct from the ACE2 binding site. It shows the neutralizing ability against SARS-CoV-2 and SARS-CoV-1 variants. This product has been determined by Enzyme-linked immunosorbent assay, Surface plasmon resonance and Neutralization assay. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 |
| Epitope | Conserved class 3 epitope site containing residues L335, V362 and P527. |
| Affinity | 257 nM |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; SPR; Neut |
| Application Notes | The antibody was evaluated by ELISA and Neutralization assay. ELISA: The antibody started at 100 μg/mL with a serial dilution. Neutralization assay: The IC50 improving from 228 ng/mL to around 10 ng/mL for SARS-CoV-2 and from 2.27 mg/mL to around 20 ng/mL for SARS-CoV-1. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 S1 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 Spike S1 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
